LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Inicio・Lista de Acciones・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Cerrado

1.25 10.62

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.13

Máximo

1.25

Métricas clave
By Trading Economics
Ingresos	17M -26M
Empleados	171
EBITDA	19M -23M

Dividendos
By Dow Jones
Próximas Ganancias	26 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-34M 68M
Apertura anterior	-9.37
Cierre anterior	1.25

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.43 / 1.6 Soporte y Resistencia

Pliant Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

18 feb 2026, 22:31 UTC

Ganancias

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18 feb 2026, 22:18 UTC

Ganancias

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18 feb 2026, 22:11 UTC

Ganancias

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18 feb 2026, 21:52 UTC

Ganancias

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18 feb 2026, 23:56 UTC

Charlas de Mercado

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18 feb 2026, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

18 feb 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18 feb 2026, 23:34 UTC

Charlas de Mercado

Ganancias

Brambles' Cost Control Stands Out to Bull -- Market Talk

18 feb 2026, 23:33 UTC

Charlas de Mercado

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18 feb 2026, 23:32 UTC

Charlas de Mercado

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18 feb 2026, 22:45 UTC

Ganancias

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18 feb 2026, 22:44 UTC

Charlas de Mercado

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18 feb 2026, 22:37 UTC

Ganancias

Nutrien 4Q EPS $1.18 >NTR.T

18 feb 2026, 22:37 UTC

Ganancias

Nutrien 4Q Sales $5.34B >NTR.T

18 feb 2026, 22:35 UTC

Ganancias

Pan American Silver 4Q EPS $1.07 >PAAS

18 feb 2026, 22:35 UTC

Ganancias

Pan American Silver 4Q Rev $1.18B >PAAS

18 feb 2026, 22:30 UTC

Ganancias

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18 feb 2026, 22:29 UTC

Ganancias

Kinross Gold 4Q EPS 75c >K.T

18 feb 2026, 22:22 UTC

Ganancias

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18 feb 2026, 22:22 UTC

Charlas de Mercado

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18 feb 2026, 22:16 UTC

Ganancias

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18 feb 2026, 22:05 UTC

Ganancias

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18 feb 2026, 22:03 UTC

Ganancias

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18 feb 2026, 22:02 UTC

Ganancias

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18 feb 2026, 22:02 UTC

Ganancias

Kaiser Aluminum 4Q Sales $929M >KALU

18 feb 2026, 22:02 UTC

Ganancias

Kaiser Aluminum 4Q EPS $1.68 >KALU

18 feb 2026, 22:00 UTC

Ganancias

Kinross Gold 4Q Adj EPS 67c >KGC

18 feb 2026, 22:00 UTC

Ganancias

Kinross Gold 4Q Sales $2.02B >KGC

18 feb 2026, 21:56 UTC

Ganancias

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18 feb 2026, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc previsión

Consenso

By TipRanks

Vender

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.